Curated News
By: NewsRamp Editorial Staff
September 30, 2026
Quantum BioPharma's Lucid-MS Advances to Phase 2 MS Trial; unbuzzd(TM) Shows Commercial Promise
TLDR
- Quantum BioPharma advances Lucid-MS to Phase 2 for multiple sclerosis and holds a 7 percent royalty on unbuzzd, offering investors a dual opportunity.
- Lucid-MS targets myelin to prevent and reverse degradation in multiple sclerosis, while unbuzzd accelerates alcohol metabolism through a separate wellness company.
- Quantum BioPharma's Lucid-MS could bring hope to multiple sclerosis patients, and unbuzzd may help reduce alcohol-related harm for many people.
- Quantum BioPharma co-founder Anthony Durkacz discussed Lucid-MS and unbuzzd on the BioMedWire Podcast, highlighting a 250 million dollar royalty cap.
Impact - Why it Matters
This news matters because Quantum BioPharma is progressing a novel drug candidate, Lucid-MS, into Phase 2 trials for multiple sclerosis, a disease with significant unmet medical need. If successful, Lucid-MS could offer a new mechanism to prevent and reverse myelin damage, potentially transforming treatment for MS patients. Additionally, the commercial development of unbuzzd(TM) provides Quantum with a royalty stream and equity stake that could generate substantial non-dilutive funding to support its biopharma pipeline. For investors, these milestones represent potential catalysts that could drive long-term value, while patients may benefit from innovative therapies for neurodegenerative and metabolic disorders.
Summary
Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma (NASDAQ: QNTM), appeared on The BioMedWire Podcast to discuss the company's promising pipeline, including its lead drug candidate Lucid-MS, which is advancing to a Phase 2 clinical trial in multiple sclerosis (MS) patients. According to Durkacz, Lucid-MS is a patented new chemical entity that targets myelin and has shown the ability to prevent and reverse myelin degradation in preclinical models. The upcoming Phase 2 trial will be the first time the drug is tested in MS patients, marking a critical milestone for Quantum and potentially offering a new therapeutic approach for this challenging neurodegenerative disease.
Durkacz also highlighted the commercial progress of unbuzzd(TM), an over-the-counter product designed to accelerate alcohol metabolism. Quantum invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and a 7% royalty on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products for pharmaceutical and medical uses. For investors seeking more information, the latest updates on QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The interview was conducted by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, and part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Advances to Phase 2 MS Trial; unbuzzd(TM) Shows Commercial Promise
